Shaobin Zhang1, Huichun Huang, Yu Zheng. 1. Shantou University/The Chinese University of Hong Kong Joint Shantou International Eye Center, Shantou 515041, China.
Abstract
PURPOSE: To evaluate the clinical effects of the low power and negative power acrylic foldable intraocular lens (AcrySof IOL) implatation through 2.6 mm incision. METHODS: Fifty-two cases (68 eyes) cataract with high myopia were performed phacoemulsification, applied Monarch II injection delivery system for IOL insertion to implant the low power and negative power AcrySof IOL through 2.6 mm incision. Intraoperative and postoperative complications, visual acuity were observed. The mean follow-up was 6 months (range, 3-12 months). RESULTS: All the IOL implantation were uneventful and no IOL damage occurred. No intraoperative complications happened. During 3 months of follow-up, the corrected visual acuity was 0.12-0.25 in 8 eyes (11.8%), 0.3-0.5 in 21 eyes (30.9%), 0.6-1.0 in 36 eyes (52.9%), more than 1.0 in 3 eyes (4.4%). Cystoid macular edema was found in 2 eyes. No retinal detachment and posterior capsular opacification were seen. CONCLUSION: It is safe and effective to applied Monarch II injection delivery system for IOL insertion to implant the low power and negative power AcrySof IOL through 2.6 mm incision.
PURPOSE: To evaluate the clinical effects of the low power and negative power acrylic foldable intraocular lens (AcrySof IOL) implatation through 2.6 mm incision. METHODS: Fifty-two cases (68 eyes) cataract with high myopia were performed phacoemulsification, applied Monarch II injection delivery system for IOL insertion to implant the low power and negative power AcrySof IOL through 2.6 mm incision. Intraoperative and postoperative complications, visual acuity were observed. The mean follow-up was 6 months (range, 3-12 months). RESULTS: All the IOL implantation were uneventful and no IOL damage occurred. No intraoperative complications happened. During 3 months of follow-up, the corrected visual acuity was 0.12-0.25 in 8 eyes (11.8%), 0.3-0.5 in 21 eyes (30.9%), 0.6-1.0 in 36 eyes (52.9%), more than 1.0 in 3 eyes (4.4%). Cystoid macular edema was found in 2 eyes. No retinal detachment and posterior capsular opacification were seen. CONCLUSION: It is safe and effective to applied Monarch II injection delivery system for IOL insertion to implant the low power and negative power AcrySof IOL through 2.6 mm incision.
Authors: Michael A Williams; Stuart McGimpsey; Salwa Abugreen; Wing Chan; James A Sharkey; Richard M Best; Patrick B Johnston Journal: Ulster Med J Date: 2009-05